Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Kotra Industries Berhad is a Malaysian pharmaceutical company specializing in the manufacture and distribution of generic and specialty drugs, primarily in Southeast Asia. The company differentiates itself through a strong focus on quality and regulatory compliance, holding certifications from various international health authorities.
Kotra generates revenue by producing generic drugs that cater to both local and international markets, leveraging its low-cost manufacturing capabilities and established distribution networks. The company benefits from strong pricing power due to its compliance with stringent regulatory standards, which enhances its reputation and customer trust.
Regulatory approvals for new drug formulations
Market expansion into new Southeast Asian countries
Changes in government healthcare policies affecting drug pricing
Competitive pricing strategies in the generic drug market
Regulatory changes impacting drug approval processes
Technological advancements in drug manufacturing that could outpace current capabilities
Intensifying competition from larger pharmaceutical companies entering the generic market
Potential price wars in the generic drug sector
Low liquidity due to free cash flow being near zero
Potential for increased operational costs if regulatory compliance becomes more stringent
moderate - The healthcare sector is somewhat insulated from economic downturns, but demand for pharmaceuticals can be influenced by overall consumer spending and government healthcare budgets.
Low - With minimal debt, Kotra's financing costs are not significantly impacted by interest rate changes; however, higher rates could affect consumer spending on healthcare products.
minimal - The company operates with low leverage, reducing its exposure to credit market fluctuations.
value - Investors may be drawn to Kotra's low valuation metrics and stable margins despite recent performance challenges.
low - The stock has shown moderate volatility, with a beta likely below 1, reflecting its stable earnings in the healthcare sector.